Other substances

Canakinumab

A human monoclonal antibody against IL-1β.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

4
 Supporting references
0
 Contradictory references
11
 AI-suggested references
6
 Clinical trials

General information

Canakinumab is a human recombinant antibody blocking IL-1β. It is used for the treatment of juvenile rheumatoid arthritis and other chronic autoinflammatory diseases (Ucciferri et al., 2020).

Canakinumab on DrugBank
Canakinumab on Wikipedia

Marketed as

ILARIS

 

Supporting references

Link Tested on Impact factor Notes Publication date
Canakinumab in a subgroup of patients with COVID-19
IL-1 Antibody Cohort study 		Patients

Fast improvement in oxygenation and decrease in the systemic inflammatory response. Sample size: 10. Dosage: 300 mg in a single subcutaneous injection.

 Jun/04/2020
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
IL-1 ARDS Case report Antibody 		Patient 5.09

Likely prevented COVID-19-related multiorgan damage (patient with ARDS and cardiac and renal failure). The patient died of pulmonary superinfection, however. Dosage: A single 300 mg subcutaneous dose on days 25 and 31.

 Oct/24/2020
Blockage of interleukin-1β with canakinumab in patients with Covid-19
IL-1 Antibody Cohort study 		Patients 4.00

Displayed efficacy for COVID-19 treatment; however, additional studies are needed (this study lacked a control group). Of the assessed laboratory parameters, increased lymphocyte count and decreased CRP levels 7 days post administration were observed. Sample size: 88. Dosage: 300 mg subcutaneously.

 Dec/11/2020
Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
IL-1 Severe severity Antibody Moderate severity Mild severity Cohort study 		Patients 2.50

Observed rapid and persistant improvement in oxygenation without severe adverse reactions. Sample size: 17 + 17 control. Dosage: Single 300 mg subcutaneous injection.

 Jan/19/2021

AI-suggested references

Link Publication date
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.
Aug/08/2020
Interleukin-1 blocking agents for treating COVID-19.
Jan/26/2022
Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.
Dec/29/2020
Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis
Dec/21/2021
Blockage of interleukin-1beta with canakinumab in patients with Covid-19
May/26/2021
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
Jul/20/2021
Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19
Jul/20/2020
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Apr/21/2020
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)
Jul/05/2021
Efficacy of canakinumab in mild or severe COVID-19 pneumonia
Jan/19/2021
Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?
Jun/28/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04476706 Canakinumab MAP in COVID-19 Pneumonia With CRS No longer available Jan/01/1970 Jan/01/1970
  • Alternative id - CACZ885D2001M
  • Interventions - Drug: canakinumab
  • Study type - Expanded Access
  • Study results - No Results Available
  • Locations -
  • Study designs -
  • Enrollment -
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures -
NCT04348448 Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia Not yet recruiting Apr/01/2020 Sep/01/2020
  • Alternative id - CANASCOV
  • Interventions - Drug: Canakinumab 150 MG/ML [Ilaris]
  • Study type - Observational
  • Study results - No Results Available
  • Locations -
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 100
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event
NCT04365153 Canakinumab in Covid-19 Cardiac Injury (The Three C Study) Completed Phase 2 Apr/24/2020 Apr/01/2021
  • Alternative id - IND 149328
  • Interventions - Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 45
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Clinical Improvement at Day 14|All-cause Mortality
NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients Not yet recruiting Phase 4 Oct/01/2021 Dec/01/2022
  • Alternative id - COVER-Main
  • Interventions - Drug: Upadacitinib|Drug: Abatacept|Drug: Secukinumab|Drug: Tofacitinib|Drug: TNF Inhibitor|Drug: Canakinumab Injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1000
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Quantitative ratio post booster vs. pre-booster of IgG against SARS-CoV-2 using electrochemiluminescent (ECL) technology against the receptor binding domain (RBD) of spike protein, stratified by treatment arm|Number of patients with score change beyond the minimal clinically important difference in the Rheumatoid Arthritis Flare Questionnaire (for patients with RA/PsA) and the BASDAI (Axial Spondyloarthritis), stratified by treatment arm|Number of patients with individual symptoms consistent with vaccine reactogenicity, as measured by the CDC Vsafe program, stratified by treatment arm
NCT04510493 Canakinumab in Patients With COVID-19 and Type 2 Diabetes Completed Phase 3 Oct/23/2020 Aug/17/2021
  • Alternative id - 2020-02008; me20Donath2
  • Interventions - Drug: Canakinumab|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University Medical Clinic Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|Hopital du Jura, Delémont, Switzerland|University Hospital Geneva, Geneva, Switzerland|University Hospital Lausanne, Lausanne, Switzerland|Cantonal Hospital Lucerne, Luzern, Switzerland|Cantonal Hospital St Gallen, St. Gallen, Switzerland|University Hospital Zürich, Zürich, Switzerland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 116
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint)|Time to clinical improvement|Death rate|Admission to intensive care unit (ICU)|Secondary worsening of disease|Prolonged hospital stay|Change in ratio to baseline in the glycated hemoglobin|Change in ratio to baseline in the fasting glucose|Change in ratio to baseline in the fasting insulin|Change in ratio to baseline in the fasting c-peptide|Ratio to baseline in the C-reactive protein (CRP)|Change in ratio to baseline in the D-dimer|Change in ratio to baseline in the Natriuretic peptide (NTproBNP)|Change in ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)|Type of antidiabetic treatment at Day 29|Number of antidiabetic treatment at Day 29|Type of antidiabetic treatment at three months|Number of antidiabetic treatment at three months
NCT04362813 Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia Completed Phase 3 Apr/30/2020 Dec/22/2020
  • Alternative id - CACZ885D2310|2020-001370-30
  • Interventions - Drug: Canakinumab|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 454
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis|COVID-19-related Death After Study Treatment|Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP)|Geometric Mean Ratio to Baseline in the D-dimer|Geometric Mean Ratio to Baseline in Ferritin|Number of Participants With Treatment Emergent Adverse Events
Export (.csv)